GlaxoSmithKline in $186 million deal with Impax for Ph III Parkinson's drug

17 December 2010

UK drugs giant GlaxoSmithKline (LSE: GSK) and Impax Pharmaceuticals, the brand products division of USA-based Impax Laboratories (Nasdaq: IPXL) have entered into an agreement for the development and commercialization of IPX066, Impax’ novel extended release carbidopa-levodopa product, worldwide excluding the USA and Taiwan.

Under the terms of the deal, Impax will receive an $11.5 million upfront payment and is eligible to receive potential payments of up to $175 million on the successful achievement of development and commercialization milestones. Impax will also receive tiered, double-digit royalty payments on GSK sales of IPX066, which the US firm will manufacture and supply to GSK.

Parkinson’s market set to grow to $6.4 billion in 2015

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK